Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories,...
-
Upload
cori-jefferson -
Category
Documents
-
view
225 -
download
0
Transcript of Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories,...
![Page 1: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/1.jpg)
![Page 2: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/2.jpg)
• Abbott Laboratories • AstraZeneca • Bristol Myer-Squibb • Cephalon • Eli Lilly & Co. • Forest Laboratories, Inc. • GalaxoSmithKline • Janssen Research • Jazz Pharmaceuticals • Lundbeck• Mallinckrodt • Merck • Novartis • Otsuka America Pharmaceuticals Inc.• Palmlabs • Pfizer, Inc. • Sanofi Aventis • Sepacor Inc. • Shire Pharmaceuticals • Somaxon Pharmaceuticals • Sunovion Pharmaceuticals Inc. • Takeda • Teva• UCB Pharma Inc. • Vaya Pharmaceuticals• Wyeth Pharmaceuticals
![Page 3: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/3.jpg)
![Page 4: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/4.jpg)
![Page 5: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/5.jpg)
![Page 6: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/6.jpg)
![Page 7: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/7.jpg)
![Page 8: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/8.jpg)
![Page 9: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/9.jpg)
HERITABILITY (GENETICS) – RELATIVE WITH BIPOLAR DISORDER AND CHILD
ODDS• One parent 25 %• Two parents 50-75%• One MZ twin 30-90%• One DZ twin 5-25 %
• American Journal of Medical Genetics Part C (Semin. Med. Genet.) 123C:48–58 (2003)
![Page 10: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/10.jpg)
![Page 11: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/11.jpg)
![Page 12: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/12.jpg)
![Page 13: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/13.jpg)
![Page 14: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/14.jpg)
Diagnostic Problems
• Time-consuming and difficult to differentiate• Subtle Symptoms• Moody ADHD/Disruptive Disorders• Non-Bipolar Depression• Pervasive Developmental Disorders (High
Functioning autistic Spectrum• Substance Use Disorders
![Page 15: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/15.jpg)
Cues that “Unipolar” Depression may be Bipolar Disorder:
• Early onset of depression• Highly recurrent depression (4 or more episodes)• Psychotic Depression• Postpartum onset of depression• History of mixed mood states• Family History of Bipolar Disorder• >3 failed antidepressant trials• Marked agitation with an antidepressant
• Manning JS Family Practice 300; 2 Supp S 6-9
![Page 16: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/16.jpg)
Qualities that differ between Bipolar D/O vs. Unipolar D/O
• Total Sleep Time BP>UP• Hypersomnia BP>UP• Psychomotor Retardation BP>UP• Postpartum Depression BP>UP• Weight Loss UP>BP
![Page 17: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/17.jpg)
![Page 18: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/18.jpg)
![Page 19: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/19.jpg)
![Page 20: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/20.jpg)
20
COMORBIDITY OF PSYCHIATRIC DISORDERS IN PEDIATRIC BIPOLAR DISORDER
Pliszka SR. Pediatr Drugs. 2003;5:741-750.
ADHD = attention deficit hyperactivity disorderCD = conduct disordersODD = oppositional defiant disorder
ADHD ODD/CD
Depression/Anxiety Disorders
Learning Disorders
Tic Disorders
Bipolar Disorder
•The rule more than the exception
•Approximately 50%-90%
•Disruptive Disorders
•Anxiety Disorders
•Substance Abuse (adolescents)
![Page 21: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/21.jpg)
Clinical Presentation of Pediatric Bipolar I Disorder
• Adolescent patients with Bipolar I Disorder are diagnosed using the same DSM-IV-TR criteria as adults
• Pediatric patients with Bipolar Disorder are more likely to present with:– Predominantly mixed episode– Rapid Cycling– Prominent irritability that may lead to violence and
explosiveness– Frequently associated with psychotic symptoms and markedly
labile mood • Often suffer from a more chronic form of the illness
characterized by longer symptomatic episodes that are often refractor to treatment
APA DSM IVAACAPPavuluri MN et al. J Am Acad Chld and Adolecnet Psychiatry 1005: 44:849-871
![Page 22: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/22.jpg)
22
CHARACTERISTICS COMMON TO PEDIATRIC MANIA
– Severe, prolonged irritability– Affective storms– Prolonged and aggressive temper outbursts–Mixed mania or rapid cycling (> 70% of
cases)– High comorbidity with ADHD– Chronic and unremitting course
Biederman J et al. Biol Psychiatry. 2000;48:458-466.State RC et al. Am J Psychiatry. 2002;159;918-925.
![Page 23: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/23.jpg)
DEFINITIONS• BIPOLAR DISORDER NOT OTHERWISE SPECIFIED (NOS): - recommended
to describe the large number of youths who receive a diagnosis of bipolar disorder who do not have the classic adult presentation 1
• Definitions currently used in the juvenile bipolar literature, but not provided in DSM-IV-TR, include the following:
– ULTRARAPID CYCLING: refers to brief, frequent manic episodes lasting hours to days, but less than the 4-day prerequisite for hypomania. Having 5 to 364 cycles per year 2
– ULTRADIAN CYCLING: refers to repeated brief (minutes to hours) cycles that occur daily. Having greater than 365 cycles per year 2
1. NIMH, 2001 2. Geller et al. (2000)
![Page 24: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/24.jpg)
Clinical course of recurrent mood disorders
![Page 25: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/25.jpg)
MEDICAL CONDITIONS THAT MAYMIMIC PEDIATRIC BIPOLAR DISORDER
• Hypothyroidism• Closed or open head injury• Temporal lobe epilepsy• Multiple Sclerosis• Systemic lupus erythematosus• Fetal alcohol spectrum disorder/ alcohol
related neurodevelopmental disorder• Wilson’ s disease
Kowatch et al. JCAAP. 2006; 15:73108
![Page 26: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/26.jpg)
FACTORS SUGGESTIVE OF PEDIATRIC BIPOLAR DISORDER
• Depression• Family history of mood disorders• Disruptive behavior & prominent mood symptoms• Psychosis• Attention-deficit / hyperactivity disorder• Poor stimulant response• History of medication-induced manic symptoms
![Page 27: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/27.jpg)
PEARLS TO HELP WITH DIAGNOSIS
• Family history (BP is highly heritable; Identical twin concordance – 70% vs. Fraternal – 20%) –Best Predictor
• Presence of elation/euphoria or grandiosity• Look at timeline of symptoms – not just current
mental status• Episodic worsening within chronic symptoms• MDD + Psychosis, psychomotor retardation,
childhood onset• History of medication-induced manic symptoms
![Page 28: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/28.jpg)
PEDIATRIC BP VS. ADHD
Mania Item Bipolar ADHD
Irritable Mood 97% 72%
Grandiosity 85% 7%
Elated Mood 87% 5%
Dare devil Acts 70% 13%
Uninhibited People Seeking
68% 21%
Silliness/Laughing 65% 21%
Flight of Ideas 66% 10%
Accelerated Speech 97% 78%
Hypersexuality 45% 8%Geller et al. J Affect Disord 1998
![Page 29: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/29.jpg)
NON-SPECIFIC SYMPTOMS
Irritability (98% vs. 72%)Accelerated Speech (97% vs. 82%)Distractability (94% vs. 96%)Unusual Energy (100% vs. 95%)
Geller et al. J Child and Adol Psychophar m.2002
![Page 30: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/30.jpg)
![Page 31: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/31.jpg)
CLINICAL PEARLS
• Difficult to diagnosis/Be sure diagnosed is correct• Select a evidence based medication regiment• Use the right doses of medication/Ensure the
medication trial continues for an adequate periods of time.
• Be aware of any psychiatric comorbitities• Carfully Assess for adverse reactions/Remove
agents that may be exacerbating situations• Combination interventions most often used
![Page 32: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/32.jpg)
Predictors of Bipolar Disorder
• MDD with• Psychosis• Psychomotor retardation• Pharmacological induced mania/hypomania• Family history of bipolar disorder
![Page 33: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/33.jpg)
… you felt so good or so hyper that other people thought you were not your normal self or you were so hyper that you got into trouble?
… you were so irritable that you shouted at people or started fights or arguments?
… you felt much more self-confident than usual?
… you got much less sleep than usual and found you didn’t really miss it?
… you were much more talkative or spoke much faster than usual?
… thoughts raced through your head or you couldn’t slowyour mind down?
Mood Disorder Questionnaire
Hirschfeld. Prim Care Companion J Clin Psychiatry. 2002;4:9-11.
Has there ever been a period of time when you were not your usual self and…
![Page 34: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/34.jpg)
![Page 35: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/35.jpg)
![Page 36: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/36.jpg)
![Page 37: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/37.jpg)
Depression Is the PredominantMood in Bipolar I Disorder
Judd LL et al. Arch Gen Psychiatry. 2002;59:530–537.
12.8-year prospective NIMH natural history study (N = 146)
• Patients with bipolar I disorder spent nearly Patients with bipolar I disorder spent nearly half of the time symptomatically illhalf of the time symptomatically ill
– Time spent depressed was Time spent depressed was 3 times more 3 times more than time spent manicthan time spent manic
– Time spent manic accounted for only 9.3% Time spent manic accounted for only 9.3% of the timeof the time
• Depression (but not mania) predicted greater Depression (but not mania) predicted greater future illness burdenfuture illness burden
![Page 38: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/38.jpg)
Maintenance Treatment to Help Maintain Stability Against Depressive
Episodes Is Particularly Important
Maintenance Treatment to Help Maintain Stability Against Depressive
Episodes Is Particularly Important
Bowden C et al. Arch Gen Psychiatry. 2003;60:392–400.Data on file, GlaxoSmithKline.
Depression: A Dominant Next Episode Among Patients Receiving Placebo During Two 18-Month Maintenance Trials
Mania29%
Depression71%
Patients currentlyor recently depressed
Mania57%
Depression43%
Patients currentlyor recently manic/hypomanic
Mood Polarity of Events in Bipolar I
Disorder
![Page 39: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/39.jpg)
![Page 40: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/40.jpg)
1. Calabrese et al. J Clin Psychiatry. 2002;63(suppl 10):18-22.2. Hirschfeld et al. Am J Psychiatry. 2002;159(4 suppl):1-50.
Treatment Objectives for Bipolar Disorder
• Bipolar disorder is a lifelong illness; therefore, maintenance treatment is the core of management1
• Treatment choice should be made by collaborative effort between patient and physician2
• The goal of acute therapy is to stabilize acute episodes with the goal of remission2
• The goal of maintenance therapy is to optimize protection against recurrence of episodes2
• Concurrently, attention needs to be devoted to maximizing patient functioning and minimizing subthreshold symptoms and adverse effects of treatment2
![Page 41: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/41.jpg)
SOMATIC TREATMENTS
• Recommendation 6. For Mania in Well-Defined DSM-IV-TR Bipolar I Disorder, Pharmacotherapy Is the Primary Treatment
![Page 42: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/42.jpg)
THE CHOICE OF MEDICATION(S) SHOULD BE MADE BASED ON:
(1) Evidence of efficacy(2) Phase of illness(3) Presence of confounding presentations (e.g.,
rapid cycling mood swings, psychotic symptoms)(4) Agent`s side effect spectrum and safety(5) Patient`s history of medication response(6) Preferences of the patient and his or her
family. A history of treatment response in parents may predict response in offspring
Duffy et al., 2002
![Page 43: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/43.jpg)
![Page 44: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/44.jpg)
• Psychosocial Treatments as an adjunct to• Medications• Parent/Family Psychoeducation• Relapse Prevention• CBT or IPT for Depression• Interpersonal and Social Rhythm Therapy• Family Focused Therapy• Community Support Programs
![Page 45: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/45.jpg)
AACAP Treatment goals for pedicatric Patients with Bipolar Disorder
• The general goals of treatment are:– Manage Symptoms and maintain response– Provide education about the illness– Promote Adherence to treatment
• AACAP Guidelines suggest using a comprehensive treatment plan, combining pharmacotherapy with behavioral/psychosocial interventions
AACAP 2007
![Page 46: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/46.jpg)
FDA APPROVED MEDICATIONS FOR PED BPD I, MIXED OR MANIC
• Airpiprazole 10-17• Olanzapine 13-17• Quetiapine 10 - 17• Risperidone 10-17• Lithium 12-10
![Page 47: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/47.jpg)
SCREENING
• Recommendation 1. Psychiatric Assessments for Children and Adolescents Should Include Screening Questions for Bipolar Disorder– Distinct mood changes associate sleep distrubances
and psychomotor activation– Family history of mood disorders– Symptoms of irritability, reckless behaviors or
increased energy– Perspective by family, school, peer, and other
psychosocial factors rather than simply using checklist
![Page 48: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/48.jpg)
ASSESSMENT
![Page 49: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/49.jpg)
ASSESSMENT (CONTINUED)
![Page 50: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/50.jpg)
Pharmacologic Treatment Goals in Bipolar Disorder
Pharmacologic Treatment Goals in Bipolar Disorder
Hirschfeld RM et al. Am J Psychiatry. 2002;159(Suppl):1–50.
Minimize subthreshold symptoms
Delay or prevent recurrence of manic or depressive episodes
Return to normal levels of psychosocial functioning
Achieve rapid control of manic symptoms
Acutephase
Maintenancephase
Achieve remission of depressive symptoms
![Page 51: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/51.jpg)
THE GOAL OF THERAPY
![Page 52: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/52.jpg)
RECOMMENDATIONS:
![Page 53: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/53.jpg)
COMPREHENSIVE TREATMENT APPROACH FOR CHILDREN AND ADOLESCENTS WITH BIPOLAR
DISORDER
Medication TherapyMedication Therapy
PsychotherapyPsychotherapyEducationalEducationalInterventionsInterventions
![Page 54: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/54.jpg)
Kowatch R, et al. 2005.Kowatch R, et al. 2005.
![Page 55: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/55.jpg)
Bipolar Disorder - Psychoeducation
• Symptomatology• Etiology ( e.g., genetics)• Treatment• Prognosis• Prevention (early signs of relapse/recurrence)• Psychosocial Scars• Stigma• Mood Hygiene• Importance of compliance
![Page 56: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/56.jpg)
56
PSYCHOSOCIAL INTERVENTIONS
– Family Therapy • Psychoeducation (Diagnosis, Treatment) • Emphasize Compliance• Mood monitoring• Social skills training• Strategies aimed at increasing life style regularity
(Adhering to regular schedule, normal sleep/wake cycle)
• Parent training in behavioral interventions to deal with problematic behavior
• Therapist helps family see family dynamics that may be contributing to patient’s illness.
![Page 57: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/57.jpg)
BIPOLAR DISORDER NO RESPONSE TO TREATMENT
• Misdiagnosis• Compliance• Adequate treatment (type, doses, duration)• Comorbidity ( e.g., substance abuse)• Exposure to Stressful Life Events (e.g., abuse)• Psychosocial Factors
![Page 58: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/58.jpg)
![Page 59: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/59.jpg)
RISK FACTORSStrong genetic component in Adults –four- to six fold increase risk of disorder in
first degree relatives of affected individuals 1
Degree of familiality appears even higher in early onset, highly comorbid cases 2
Premorbid psychiatric problems are common in early-onset bipolar disorder,
especially difficulties with disruptive behavior disorders, irritability, and behavioral dyscontrol 3
Most childhood cases are associated with Attention Deficit Hyperactivity Disorder 4
In those whose first mood episode is a depressive disorder. Approximately 20% of
youths with major depression go on to experience manic episodes by adulthood 5
1. Nurnberg and Foroud, 20002. Faraone et al., 20033. Carlson, 1990; Fergus et al., 2003; Geller et al., 2002a; McClellan et al., 2003; Werry et al., 1991; Wozniak et al., 1995)4. Findling et al. 2001; Geller et al., 2002a; Wozniak et al., 1995).5. Geller et al., 1994, 2001; Kovacs, 1996; Rao et al., 1995; Strober and Carlson, 1982).
![Page 60: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/60.jpg)
*76% of patient cohort were patients with bipolar I disorder.1. Judd LL et al. Arch Gen Psychiatry. 2002;59:530–537.2. Post RM et al. Clin Neurosci Res. 2002;2:142–157.
Based on the 12.8-year NIMH natural history study (n = 146), of the 47% of time spent symptomatically ill, patients experienced depressive symptoms 3
times more than manic symptoms1
• In another naturalistic study, patients treated for bipolar disorder experienced 121 days of depression, versus 40 of mania, in a single year2*
Tim
e sp
ent s
ympt
omati
cally
ill (
%)
67%
20%13%
Depressed
Cycling/mixed Manic
Depression is the Predominant MoodDepression is the Predominant Moodin Bipolar I Disorderin Bipolar I DisorderDepression is the Predominant MoodDepression is the Predominant Moodin Bipolar I Disorderin Bipolar I Disorder
![Page 61: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/61.jpg)
PROGNOSITIC INDICATORS:• Good• Short Duration of manic episodes• Advanced age of onset• Few suicidal thoughts• Few coexisting psychiatric disorder• Few medical problems• • Poor• Poor premorbid occupational status• Alcohol Dependence• Psychotic features• Depressive features• Interepisode depressive features• Male gender• coexisting psychiatric disorder
![Page 62: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/62.jpg)
BIPOLAR DISORDER - SEQUELA
• Poor academic functioning• Interpersonal and family difficulties• Increased risk for suicide• Increased use of tobacco, alcohol, and other
substances• Behavior problems• Legal difficulties• Increased health services utilization (e.g.,
hospitalizations)
Emslie GJ, Mayes TL. Biol Psychiatry. 2001;49:1082-1090.
![Page 63: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/63.jpg)
![Page 64: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/64.jpg)
![Page 65: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/65.jpg)
![Page 66: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/66.jpg)
Estimated Total Lifetime Cost per Case by Prognosis Group
Begley et al. Pharmacoeconomics. 2001;19(5 pt 1):483-495.
Thou
sand
s of
dol
lars
, 199
8Th
ousa
nds
o f d
olla
rs, 1
998
![Page 67: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/67.jpg)
![Page 68: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/68.jpg)
HEADACHE IN TEENS WITH BIPOLAR DISORDER
• Unpublished, presented at AACAP• Canadian teens, bipolar d/o• 55 outpts., 13 y/o-19 y/o BP I, II, NOS• 60% F, 60% with HA – Sig. > severity on depressive,
manic and CGI• Teens with BP with HA Sig. rates of identity confusion,
anger/depression, and disinhibition /persistence • Results BP teen w/ HA more prone to > severity than
BP teens w/o• Psy. Hosp. and psychosis > BP teen without headaches-
results counterintuitive
![Page 69: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/69.jpg)
HEADACHE IN TEENS WITH BIPOLAR DISORDER (Cont.)
• Rational: – 1) BP teens with HA a different subtype? –unique
course, characterisics and perhaps treatment?– 2) under dx or tx in adult BP and headaches is well
doc. Potential treating in youth is important.
![Page 70: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/70.jpg)
![Page 71: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/71.jpg)
Summary
• Difficult to diagnosis
• Comorbidity
• Comprehensive treatments
• Goals and re-evaluation
• Prognosis?
![Page 72: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/72.jpg)
Unmet Needs in Pediatric Bipolar Disorder
• Diagnostic Criteria
• Faster improvement
• Fewer side effects and better tolerability
• Greater efficacy
• Long term efficacy
Source: Datamonitor, Stakeholder Insight: MDD, Q1.2; Adult population figures from www.census.gov and MDD prevalence rates applied.
![Page 73: Abbott Laboratories AstraZeneca Bristol Myer-Squibb Cephalon Eli Lilly & Co. Forest Laboratories, Inc. GalaxoSmithKline Janssen Research Jazz Pharmaceuticals.](https://reader035.fdocuments.in/reader035/viewer/2022062216/56649d9e5503460f94a88be6/html5/thumbnails/73.jpg)
RESOURCESWEBSITES:– The Child and Adolescent Bipolar
Foundation• www.bpkids.org
– Depression and Bipolar Support Alliance• www.dbsalliance.org
– The Bipolar Child• www.bipolarchild.com
– Parents of Bipolar Children• www.bpparent.org
– The Gray Center for Social Learning and Understanding• www.thegraycenter.org/Social_Stories.htm
– National Institute of Mental Health (NIMH)• www.nimh.org